The Macular Minute Episode 8
with Richard Gale
Adverse Event Management for EYLEA® (aflibercept) 8 mg
In this 2-minute episode, we are joined by Richard Gale, a Consultant Ophthalmologist at York and Scarborough Teaching Hospitals NHS Foundation Trust, to discuss the management and minimisation of adverse events with EYLEA 8 mg in UK medical retina clinics.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Richard Gale
Richard Gale is a Professor of Ophthalmology at York University and an Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust. He leads a team of researchers in Ophthalmology and Clinical Visual Science with particular focus on macular degeneration. Richard has published over 100 scientific papers and book chapters and is a Joint Ophthalmology Specialty Lead for the NIHR Clinical Research Network Yorkshire and Humber and holds the position of deputy chair for the National Ophthalmology Specialty Group (Northern).
Speaker Disclosures
Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen,
Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen
References
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2548 | December 2024